Overview

Detailed Summary

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas.
In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance.
The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders.
Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments.
Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,324 Cr
Volatility: Low Risk
P/E Ratio: 30.7
Industry P/E: 34.1
PEG Ratio: 0.7
P/B Ratio: 4.8
52W High: 301.80
52W Low: 154.90

Sales CAGR

1Y: 28.76%
3Y: 7.29%
5Y: 11.13%
10Y: 7.16%

Profit CAGR

1Y: 146.48%
3Y: 43.19%
5Y: 47.72%
10Y: 37.01%

ROE

TTM: 15.60%
3Y: 17.83%
5Y: 16.70%
10Y: 11.68%

ROCE

TTM: 20.59%
3Y: 22.13%
5Y: 21.17%
10Y: 15.61%

Technicals

Oscillators

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
INDSWFTLAB		163.90	1,405 Cr	33.94	1.02	0.00	3.57	4.36	2.47
SYNCOMF		14.55	1,371 Cr	17.93	3.30	0.00	18.42	24.46	14.32
SHUKRAPHAR		30.98	1,348 Cr	61.12	15.00	0.00	24.55	31.50	18.78
JAGSNPHARM		201.05	1,324 Cr	30.72	4.80	2.02	15.60	20.59	13.60
LINCOLN		637.35	1,277 Cr	14.52	1.68	0.28	11.60	15.18	9.87
FREDUN		2311.25	1,274 Cr	34.01	4.50	0.03	11.73	15.97	5.83
ACCENTMIC		475.85	1,142 Cr	26.03	4.14	0.21	15.92	21.28	13.63
Median: 7 Co.	—	201.05	1,324 Cr	30.72	4.14	0.03	15.60	20.59	13.60

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	47	43	61	75	74	59	76	74	73	64
Expenses	44	41	51	58	58	50	61	58	57	53
Operating Profit	3.39	2.67	10	16	16	8.72	14	16	16	11
OPM %	7.18	6.14	16.67	21.80	21.40	14.89	18.79	22.08	22.32	17.38
Other Income	2.52	2.49	-1.85	1.65	26	2.56	2.83	3.03	0.90	3.17
Interest	0.23	0.22	0.22	0.23	0.26	0.26	0.25	0.27	0.26	0.25
Depreciation	0.41	0.40	1.07	2.34	2.41	2.31	2.35	2.39	2.39	2.32
Profit Before Tax	5.28	4.54	7.11	15	39	8.71	14	17	15	12
Tax %	25.00	21.81	25.04	25.44	17.27	24.45	25.23	25.22	24.59	25.43
Net Profit	3.96	3.55	5.33	11	32	6.58	11	13	11	8.76
EPS in Rs	0.58	0.52	0.76	1.68	1.88	0.97	1.57	1.86	1.65	1.21

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	145	127	167	159	188	218	237	209	269	283
Expenses	138	138	157	150	169	193	203	186	218	228
Operating Profit	6.97	-11	9.34	8.53	19	25	34	23	51	55
OPM %	4.80	-8.72	5.60	5.38	10.15	11.50	14.43	11.05	19.01	19.46
Other Income	13	0.46	1.43	2.53	4.39	3.43	2.28	9.28	28	33
Interest	2.64	0.66	0.75	0.51	0.51	0.29	0.41	0.81	0.96	1.00
Depreciation	1.99	0.32	1.02	1.13	1.09	1.53	1.21	1.66	8.13	9.41
Profit Before Tax	14	-12	9.00	9.41	22	27	35	30	70	77
Tax %	17.59	0.65	19.85	16.40	22.01	29.23	23.23	24.79	20.75	21.18
Net Profit	12	-12	7.22	7.87	17	19	27	22	55	61
EPS in Rs	1.77	-1.73	1.08	1.17	2.55	2.81	3.99	3.32	5.29	6.29
Dividend Payout %	2.21	-2.27	9.09	16.67	15.36	55.56	49.02	59.03	30.41	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	13	13	13	13	13	13	13	13	13
Reserves	85	97	85	91	98	109	120	146	174	227
Borrowings	38	7.93	8.30	3.79	4.66	6.79	0.00	6.00	8.94	9.24
Other Liabilities	22	25	23	28	31	35	31	30	21	29
Total Liabilities	159	143	130	136	147	164	164	195	217	278
Fixed Assets	52	22	21	22	22	26	23	24	9.30	94
CWIP	0.00	0.00	3.04	3.95	4.25	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	11	15	51	1.12	0.00	0.00
Other Assets	108	121	105	110	109	123	91	170	208	184
Total Assets	159	143	130	136	147	164	164	195	217	278

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	9.04	-3.24	-1.58	31	11	28	6.91	47	35	55
Cash from Investing Activity	-2.09	41	-3.37	-0.83	-11	-2.26	-26	-58	-25	-45
Cash from Financing Activity	-6.43	-34	-0.60	-6.05	-0.94	-6.83	-18	-0.46	-8.91	-12
Net Cash Flow	0.52	4.53	-5.55	24	-0.46	19	-36	-11	1.71	-1.55

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	68.71%	68.71%	68.48%	68.09%	68.04%	67.97%	67.81%	67.78%	67.65%	67.54%	67.39%	67.89%
FIIs	0.37%	0.38%	0.53%	0.73%	1.10%	2.30%	2.10%	2.10%	2.18%	2.12%	2.12%	2.44%
DIIs	0.83%	0.83%	0.82%	0.85%	0.85%	0.11%	0.00%	0.00%	0.05%	0.09%	0.15%	0.22%
Public	30.08%	30.08%	30.17%	30.33%	30.01%	29.62%	30.08%	30.11%	30.12%	30.25%	30.34%	29.45%
Total Shareholders	13,782	16,041	15,785	16,282	15,748	15,633	18,471	21,085	22,899	24,653	24,895	26,264

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Available on Pro Plan